Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression

Journal of Infectious Diseases

Volumn 182, Issue 4, 2000, Pages 1063-1069

  Kovacs, Joseph A ^a   Imamichi, Hiromi ^c   Vogel, Susan ^b   Metcalf, Julia A ^b   Dewar, Robin L ^c   Baseler, Michael ^c   Stevens, Randy ^c   Adelsberger, Joseph ^c   Lambert, Laurie ^c   Davey, Richard T ^b   Walker, Robert E ^b,d   Falloon, Judith ^b   Polis, Michael A ^b   Masur, Henry ^a   Lane, H Clifford ^b  

^a CLINICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE; VIRUS LOAD;

ADULT; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMAN; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; LONGITUDINAL STUDIES; MALE; PHYLOGENY; POLYMERASE CHAIN REACTION; RNA, VIRAL; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 0033801154     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315821     Document Type: Article

References (31)

1. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
2. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type I infection
3. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
4. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV 1 infection: A randomised controlled trial. ANRS 048 study group
5. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study
6. Subcutaneous administration of interleukin 2 in human immunodeficiency virus type 1-infected persons
7. Interleukin-2 infusions in HIV-infected patients
8. Presence of an inducible HIV 1 latent reservoir during highly active antiretroviral therapy
9. Identification of a reservoir for HIV 1 in patients on highly active antiretroviral therapy
10. Recovery of replication competent HIV despite prolonged suppression of plasma viremia
11. + T cells in HIV-infected patients receiving highly active antiretroviral therapy
12. Toward HIV eradication or remission: The tasks ahead
13. Application of branched DNA signal amplification to monitor human immunodeficiency virus type I burden in human plasma
14. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
15. Intra assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma
16. CLUSTAL W: Improving the sensitivity of progressive multiple-sequence alignment through sequence weighting, position specific gap penalties, and weight matrix choice
17. The neighbor joining method: A new method for reconstructing phylogenetic trees
18. MODELTEST: Testing the model of DNA substitution
19. Confidence limits on phylogenies: An approach using the bootstrap
20. MK 639 (Merck HIV protease inhibitor) with interleukin-2 in HIV
21. Tumor necrosis factor-α induces expression of human immunodeficiency virus in a chronically infected T cell clone
22. GM-CSF and its effects on replication of HIV 1 in cells of macrophage lineage
23. Cytokine induced expression of HIV I in a chronically infected promonocyte cell line
24. Interleukin-10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor-α and interleukin-6 induction of virus
25. Interleukin-10 decreases HIV plasma viral load: Results of a phase I clinical trial
26. + T cells and this effect overrides its ability to stimulate virus expression
27. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
28. Indinavir and interleukin-2 in HIV: One-year follow up
29. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
30. Visceral abdominal fat accumulation associated with use of indinavir
31. Duration of proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion